Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 3 boards, counting each seat separately. Longest: Coherus Oncology Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Keros Therapeutics Inc. June 3, 202696.5%
-
Novavax Inc. June 20, 202574.6%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 18, 2026 | Keros Therapeutics Inc. | Open-market sale | −551 | $10.30 | $5,675 |
| Jun 11, 2026 | Keros Therapeutics Inc. | Open-market sale | −550 | $10.04 | $5,522 |
| Jun 5, 2026 | Coherus Oncology Inc. | Grant or award | +30,000 | — | — |
| Apr 25, 2026 | Novavax Inc. | Option exercise | +9,520 | — | — |
| Mar 9, 2026 | Keros Therapeutics Inc. | Grant or award | +13,215 | — | — |
| Aug 21, 2025 | Lyell Immunopharma Inc. | Open-market sale | −1,453 | $10.54 | $15,315 |
| Aug 20, 2025 | Lyell Immunopharma Inc. | Grant or award | +8,000 | — | — |
| Aug 12, 2025 | Lyell Immunopharma Inc. | Open-market sale | −136 | $10.34 | $1,406 |
| Aug 11, 2025 | Lyell Immunopharma Inc. | Open-market sale | −131 | $10.53 | $1,379 |
| Mar 17, 2025 | Lyell Immunopharma Inc. | Open-market purchase | +200,000 | $0.56 | $112,000 |
| Feb 10, 2025 | Lyell Immunopharma Inc. | Grant or award | +112,500 | — | — |
| Feb 9, 2024 | Lyell Immunopharma Inc. | Grant or award | +40,000 | — | — |
Questions about Charles W. Newton
What boards is Charles W. Newton on?
Charles W. Newton sits on the boards of Coherus Oncology Inc., Keros Therapeutics Inc. and Novavax Inc.
How long has Charles W. Newton served on boards?
Our records show at least 6 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.